B
Bull
Bull · 25%SERA
$2.12
Szenariopreis
$2.080
-0.039 (-1.89%)Zum Schluss
Loading chart…
- High
- 2.150
- Open
- 2.150
- VWAP
- 2.12
- Vol
- 14.67K
- Mkt Cap
- 186.78M
- Low
- 2.130
- Amount
- 31.10K
- EV/EBITDA, TTM
- -0.13
Sera Prognostics, Inc. is a women's health diagnostic company utilizing its proprietary proteomics and bioinformatics platform, and significant data resources to enhance maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. It has built a proteomics and bioinformatics platform to characterize the biology of pregnancy and to discover and validate key protein biomarkers found in blood that are accurate predictors of dynamic changes that occur during pregnancy. Its commercial product, the PreTRM test, is a validated, commercially available blood-based biomarker test to predict the risk of a premature delivery, also known as preterm birth. The PreTRM test is a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation that provides a prediction of the expectant mother’s risk of delivering spontaneously before 37 weeks’ gestation.
AI analysis of Sera Prognostics Inc (SERA)
holdSera Prognostics Inc is not a strong buy at the current price of $2.07 due to ongoing financial losses and insider selling, despite a bullish analyst price target of $6.
Bewertungskennzahlen
The current forward P/E ratio for Sera Prognostics Inc (SERA) is 0.00, compared to its 5-year average forward P/E of -4.30.
Alphio AI Price Scenarios for SERA
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding SERA
Event-Zeitleiste
News
- 8.508-25PRnewswire
New Breakthrough in Preterm Birth Risk Detection
9.508-19NASDAQ.COMSera Prognostics Reports Q2 2026 Financial Highlights and Strategic Developments
5.008-19PRnewswireSera Prognostics Appoints New CFO to Drive Growth
8.507-09PRnewswireSera Prognostics Study Enhances Pregnancy Care Efficiency and Cost Savings
8.506-24PRnewswireSera Prognostics Secures $10.4 Million Research Grant for Maternal Health
SERA FAQ — answered by Alphio AI
Sera Prognostics, Inc. is a women's health diagnostic company utilizing its proprietary proteomics and bioinformatics platform, and significant data resources to enhance maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. It has built a proteomics and bioinformatics platform to characterize the biology of pregnancy and to discover and validate key protein biomarkers found in blood that are accurate predictors of dynamic changes that occur during pregnancy. Its commercial product, the PreTRM test, is a validated, commercially available blood-based biomarker test to predict the risk of a premature delivery, also known as preterm birth. The PreTRM test is a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation that provides a prediction of the expectant mother’s risk of delivering spontaneously before 37 weeks’ gestation. It operates in the Industrials sector (SERVICES-MEDICAL LABORATORIES industry).
Sera Prognostics Inc is not a strong buy at the current price of $2.07 due to ongoing financial losses and insider selling, despite a bullish analyst price target of $6.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.